Neil Graham, who worked as chief medical officer at XTK Biopharmaceuticals, is the new chief medical officer at Trimeris.

Graham also will serve as senior vice president of clinical development and medical affairs.

Lynn Smiley, who was senior VP for clinical research, takes over as senior VP for regulatory affairs, compliance and drug safety.

The company announced the changes on Thursday.

Graham has an extensive background in working with anti-viral HIV drugs as well as hepatitis B and C. At one time he directed development of HIV drug development at Glaxo Wellcome (now GSK).

“Dr. Graham brings a superb reputation and an outstanding profile of experience in all phases of anti-viral drug development, and we are very excited to have someone of his caliber join the executive team of Trimeris,” said Steven Skolsky, Trimeris’ chief executive officer.

Trimeris sells its own HIV drug, Fuzeon, in global markets.